Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

"Designer cytokines" targeting the tumor vasculature-think global and act local.

Kammertoens T, Kemna J, Leisegang M.

EMBO Mol Med. 2020 Feb 7;12(2):e11801. doi: 10.15252/emmm.201911801. Epub 2020 Jan 9.

2.

Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors.

Schreiber K, Karrison TG, Wolf SP, Kiyotani K, Steiner M, Littmann ER, Pamer EG, Kammertoens T, Schreiber H, Leisegang M.

Cancer Immunol Res. 2020 Feb;8(2):192-202. doi: 10.1158/2326-6066.CIR-19-0567. Epub 2019 Dec 12.

PMID:
31831634
3.

High Salt Inhibits Tumor Growth by Enhancing Anti-tumor Immunity.

Willebrand R, Hamad I, Van Zeebroeck L, Kiss M, Bruderek K, Geuzens A, Swinnen D, Côrte-Real BF, Markó L, Lebegge E, Laoui D, Kemna J, Kammertoens T, Brandau S, Van Ginderachter JA, Kleinewietfeld M.

Front Immunol. 2019 Jun 4;10:1141. doi: 10.3389/fimmu.2019.01141. eCollection 2019.

4.

Interferon-γ Receptor Signaling in Dendritic Cells Restrains Spontaneous Proliferation of CD4+ T Cells in Chronic Lymphopenic Mice.

Knop L, Frommer C, Stoycheva D, Deiser K, Kalinke U, Blankenstein T, Kammertoens T, Dunay IR, Schüler T.

Front Immunol. 2019 Feb 7;10:140. doi: 10.3389/fimmu.2019.00140. eCollection 2019.

5.

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, Sommermeyer D, Engels B, Leisegang M, Textor A, Fehling HJ, Fruttiger M, Lohoff M, Herrmann A, Yu H, Weichselbaum R, Uckert W, Hübner N, Gerhardt H, Beule D, Schreiber H, Blankenstein T.

Nature. 2017 May 4;545(7652):98-102. doi: 10.1038/nature22311. Epub 2017 Apr 26.

6.

Targeting human melanoma neoantigens by T cell receptor gene therapy.

Leisegang M, Kammertoens T, Uckert W, Blankenstein T.

J Clin Invest. 2016 Mar 1;126(3):854-8. doi: 10.1172/JCI83465. Epub 2016 Jan 25.

7.

Composition of intestinal microbiota in immune-deficient mice kept in three different housing conditions.

Thoene-Reineke C, Fischer A, Friese C, Briesemeister D, Göbel UB, Kammertoens T, Bereswill S, Heimesaat MM.

PLoS One. 2014 Nov 17;9(11):e113406. doi: 10.1371/journal.pone.0113406. eCollection 2014.

8.

IL-13 but not IL-4 signaling via IL-4Rα protects mice from papilloma formation during DMBA/TPA two-step skin carcinogenesis.

Rothe M, Quarcoo D, Chashchina AA, Bozrova SV, Qin Z, Nedospasov SA, Blankenstein T, Kammertoens T, Drutskaya MS.

Cancer Med. 2013 Dec;2(6):815-25. doi: 10.1002/cam4.145. Epub 2013 Oct 22.

9.

Targeting c-MYC with T-cells.

Helm F, Kammertoens T, Lehmann FM, Wilke A, Bruns H, Mautner J, Bornkamm GW, Gerbitz A.

PLoS One. 2013 Oct 10;8(10):e77375. doi: 10.1371/journal.pone.0077375. eCollection 2013.

10.

It's the peptide-MHC affinity, stupid.

Kammertoens T, Blankenstein T.

Cancer Cell. 2013 Apr 15;23(4):429-31. doi: 10.1016/j.ccr.2013.04.004.

11.

Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens.

Zhang J, Chen L, Liu X, Kammertoens T, Blankenstein T, Qin Z.

Cancer Res. 2013 May 1;73(9):2770-81. doi: 10.1158/0008-5472.CAN-12-3022. Epub 2013 Mar 28.

12.

Fas expression by tumor stroma is required for cancer eradication.

Listopad JJ, Kammertoens T, Anders K, Silkenstedt B, Willimsky G, Schmidt K, Kuehl AA, Loddenkemper C, Blankenstein T.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2276-81. doi: 10.1073/pnas.1218295110. Epub 2013 Jan 22.

13.

Differences in serum cytokine levels between wild type mice and mice with a targeted mutation suggests necessity of using control littermates.

Briesemeister D, Friese C, Isern CC, Dietz E, Blankenstein T, Thoene-Reineke C, Kammertoens T.

Cytokine. 2012 Dec;60(3):626-33. doi: 10.1016/j.cyto.2012.07.019. Epub 2012 Aug 17.

PMID:
22902947
14.

Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice.

Gerbitz A, Sukumar M, Helm F, Wilke A, Friese C, Fahrenwaldt C, Lehmann FM, Loddenkemper C, Kammertoens T, Mautner J, Schmitt CA, Blankenstein T, Bornkamm GW.

PLoS One. 2012;7(3):e34552. doi: 10.1371/journal.pone.0034552. Epub 2012 Mar 30.

15.

B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-α, perforin).

Kammertoens T, Qin Z, Briesemeister D, Bendelac A, Blankenstein T.

Int J Cancer. 2012 Oct 1;131(7):1499-508. doi: 10.1002/ijc.27411. Epub 2012 Jan 31.

16.

Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.

Anders K, Buschow C, Herrmann A, Milojkovic A, Loddenkemper C, Kammertoens T, Daniel P, Yu H, Charo J, Blankenstein T.

Cancer Cell. 2011 Dec 13;20(6):755-67. doi: 10.1016/j.ccr.2011.10.019.

17.

Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis.

Briesemeister D, Sommermeyer D, Loddenkemper C, Loew R, Uckert W, Blankenstein T, Kammertoens T.

Int J Cancer. 2011 Jan 15;128(2):371-8. doi: 10.1002/ijc.25350. Epub 2010 Mar 23.

18.

Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia.

Shalapour S, Eckert C, Seeger K, Pfau M, Prada J, Henze G, Blankenstein T, Kammertoens T.

J Mol Med (Berl). 2010 Mar;88(3):249-65. doi: 10.1007/s00109-009-0583-8. Epub 2010 Feb 14.

PMID:
20155409
19.

Making and circumventing tolerance to cancer.

Kammertoens T, Blankenstein T.

Eur J Immunol. 2009 Sep;39(9):2345-53. doi: 10.1002/eji.200939612.

20.

Adaptive peripheral immune response increases proliferation of neural precursor cells in the adult hippocampus.

Wolf SA, Steiner B, Wengner A, Lipp M, Kammertoens T, Kempermann G.

FASEB J. 2009 Sep;23(9):3121-8. doi: 10.1096/fj.08-113944. Epub 2009 May 11.

PMID:
19433626
21.

CD4-positive T lymphocytes provide a neuroimmunological link in the control of adult hippocampal neurogenesis.

Wolf SA, Steiner B, Akpinarli A, Kammertoens T, Nassenstein C, Braun A, Blankenstein T, Kempermann G.

J Immunol. 2009 Apr 1;182(7):3979-84. doi: 10.4049/jimmunol.0801218.

22.

Neuroimmune crosstalk in asthma: dual role of the neurotrophin receptor p75NTR.

Nassenstein C, Kammertoens T, Veres TZ, Uckert W, Spies E, Fuchs B, Krug N, Braun A.

J Allergy Clin Immunol. 2007 Nov;120(5):1089-96. Epub 2007 Aug 22.

PMID:
17716721
23.

Cross-talk between T cells and innate immune cells is crucial for IFN-gamma-dependent tumor rejection.

Li Z, Pradera F, Kammertoens T, Li B, Liu S, Qin Z.

J Immunol. 2007 Aug 1;179(3):1568-76.

24.

The translocation motif of hepatitis B virus improves protein vaccination.

Bleifuss E, Kammertoens T, Hutloff A, Quarcoo D, Dorner M, Straub P, Uckert W, Hildt E.

Cell Mol Life Sci. 2006 Mar;63(5):627-35.

PMID:
16482397
25.

Immunotherapy: target the stroma to hit the tumor.

Kammertoens T, Schüler T, Blankenstein T.

Trends Mol Med. 2005 May;11(5):225-31. Review.

PMID:
15882610
26.

CY15, a malignant histiocytic tumor that is phenotypically similar to immature dendritic cells.

Kammertoens T, Willebrand R, Erdmann B, Li L, Li Y, Engels B, Uckert W, Blankenstein T.

Cancer Res. 2005 Apr 1;65(7):2560-4.

27.

Tumor-induced antibodies resemble the response to tissue damage.

Preiss S, Kammertoens T, Lampert C, Willimsky G, Blankenstein T.

Int J Cancer. 2005 Jun 20;115(3):456-62.

28.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.

Stelljes M, Strothotte R, Pauels HG, Poremba C, Milse M, Specht C, Albring J, Bisping G, Scheffold C, Kammertoens T, Oelmann E, Silling G, Berdel WE, Kienast J.

Blood. 2004 Aug 15;104(4):1210-6. Epub 2004 Apr 15.

PMID:
15090450
29.
30.

CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells.

Lindencrona JA, Preiss S, Kammertoens T, Schüler T, Piechocki M, Wei WZ, Seliger B, Blankenstein T, Kiessling R.

Int J Cancer. 2004 Mar 20;109(2):259-64.

31.

A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.

Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T.

Cancer Res. 2003 Jul 15;63(14):4095-100.

32.

Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8(+) T cells.

Schüler T, Kammertoens T, Preiss S, Debs P, Noben-Trauth N, Blankenstein T.

J Exp Med. 2001 Dec 17;194(12):1767-75.

33.

Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis.

Beltinger C, Fulda S, Kammertoens T, Uckert W, Debatin KM.

Cancer Res. 2000 Jun 15;60(12):3212-7.

34.

Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.

Kammertoens T, Gelbmann W, Karle P, Alton K, Saller R, Salmons B, Günzburg WH, Uckert W.

Cancer Gene Ther. 2000 Apr;7(4):629-36.

35.

Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype.

Uckert W, Becker C, Gladow M, Klein D, Kammertoens T, Pedersen L, Blankenstein T.

Hum Gene Ther. 2000 May 1;11(7):1005-14.

PMID:
10811229
36.

Impact of V beta 8+/+ T cells on the development of increased airway reactivity and IgE production in SJL mice.

Herz U, Kammertoens T, Rosenbaum J, da Palma JC, Rimm I, Renz H.

Eur J Immunol. 1999 Sep;29(9):3028-34.

37.

Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases.

Beltinger C, Fulda S, Kammertoens T, Meyer E, Uckert W, Debatin KM.

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8699-704.

Supplemental Content

Loading ...
Support Center